Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Clin Infect Dis ; 75(10): 1706-1713, 2022 11 14.
Article in English | MEDLINE | ID: mdl-35451002

ABSTRACT

BACKGROUND: Tolerance is the ability of bacteria to survive transient exposure to high concentrations of a bactericidal antibiotic without a change in the minimal inhibitory concentration, thereby limiting the efficacy of antimicrobials. The study sought to determine the prevalence of tolerance in a prospective cohort of E. coli bloodstream infection and to explore the association of tolerance with reinfection risk. METHODS: Tolerance, determined by the Tolerance Disk Test (TDtest), was tested in a prospective cohort of consecutive patient-unique E. coli bloodstream isolates and a collection of strains from patients who had recurrent blood cultures with E. coli (cohorts 1 and 2, respectively). Selected isolates were further analyzed using time-dependent killing and typed using whole-genome sequencing. Covariate data were retrieved from electronic medical records. The association between tolerance and reinfection was assessed by the Cox proportional-hazards regression and a Poisson regression models. RESULTS: In cohort 1, 8/94 isolates (8.5%) were tolerant. Using multivariate analysis, it was determined that the risk for reinfection in the patients with tolerant index bacteremia was significantly higher than for patients with a nontolerant strain, hazard ratio, 3.98 (95% confidence interval, 1.32-12.01). The prevalence of tolerance among cohort 2 was higher than in cohort 1, 6/21(28.6%) vs 8/94 (8.5%), respectively (P = .02). CONCLUSIONS: Tolerant E. coli are frequently encountered among bloodstream isolates and are associated with an increased risk of reinfection. The TDtest appears to be a practicable approach for tolerance detection and could improve future patient management.


Subject(s)
Bacteremia , Escherichia coli Infections , Humans , Escherichia coli , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Prospective Studies , Prevalence , Reinfection , Escherichia coli Infections/drug therapy , Bacteremia/microbiology
2.
Nature ; 600(7888): 290-294, 2021 12.
Article in English | MEDLINE | ID: mdl-34789881

ABSTRACT

Stress responses allow cells to adapt to changes in external conditions by activating specific pathways1. Here we investigate the dynamics of single cells that were subjected to acute stress that is too strong for a regulated response but not lethal. We show that when the growth of bacteria is arrested by acute transient exposure to strong inhibitors, the statistics of their regrowth dynamics can be predicted by a model for the cellular network that ignores most of the details of the underlying molecular interactions. We observed that the same stress, applied either abruptly or gradually, can lead to totally different recovery dynamics. By measuring the regrowth dynamics after stress exposure on thousands of cells, we show that the model can predict the outcome of antibiotic persistence measurements. Our results may account for the ubiquitous antibiotic persistence phenotype2, as well as for the difficulty in attempts to link it to specific genes3. More generally, our approach suggests that two different cellular states can be observed under stress: a regulated state, which prepares cells for fast recovery, and a disrupted cellular state due to acute stress, with slow and heterogeneous recovery dynamics. The disrupted state may be described by general properties of large random networks rather than by specific pathway activation. Better understanding of the disrupted state could shed new light on the survival and evolution of cells under stress.


Subject(s)
Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , Escherichia coli/growth & development , Microbial Viability/drug effects , Stress, Physiological/physiology , Escherichia coli/cytology , Food Deprivation , Single-Cell Analysis , Time Factors
3.
Proc Natl Acad Sci U S A ; 116(29): 14734-14739, 2019 07 16.
Article in English | MEDLINE | ID: mdl-31262806

ABSTRACT

Understanding the evolution of microorganisms under antibiotic treatments is a burning issue. Typically, several resistance mutations can accumulate under antibiotic treatment, and the way in which resistance mutations interact, i.e., epistasis, has been extensively studied. We recently showed that the evolution of antibiotic resistance in Escherichia coli is facilitated by the early appearance of tolerance mutations. In contrast to resistance, which reduces the effectiveness of the drug concentration, tolerance increases resilience to antibiotic treatment duration in a nonspecific way, for example when bacteria transiently arrest their growth. Both result in increased survival under antibiotics, but the interaction between resistance and tolerance mutations has not been studied. Here, we extend our analysis to include the evolution of a different type of tolerance and a different antibiotic class and measure experimentally the epistasis between tolerance and resistance mutations. We derive the expected model for the effect of tolerance and resistance mutations on the dynamics of survival under antibiotic treatment. We find that the interaction between resistance and tolerance mutations is synergistic in strains evolved under intermittent antibiotic treatment. We extend our analysis to mutations that result in antibiotic persistence, i.e., to tolerance that is conferred only on a subpopulation of cells. We show that even when this population heterogeneity is included in our analysis, a synergistic interaction between antibiotic persistence and resistance mutations remains. We expect our general framework for the epistasis in killing conditions to be relevant for other systems as well, such as bacteria exposed to phages or cancer cells under treatment.


Subject(s)
Drug Resistance, Bacterial/genetics , Drug Tolerance/genetics , Epistasis, Genetic , Escherichia coli/genetics , Gene Expression Regulation, Bacterial , Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , Escherichia coli/growth & development , Evolution, Molecular , Microbial Sensitivity Tests , Models, Genetic , Mutation
4.
Science ; 355(6327): 826-830, 2017 02 24.
Article in English | MEDLINE | ID: mdl-28183996

ABSTRACT

Controlled experimental evolution during antibiotic treatment can help to explain the processes leading to antibiotic resistance in bacteria. Recently, intermittent antibiotic exposures have been shown to lead rapidly to the evolution of tolerance-that is, the ability to survive under treatment without developing resistance. However, whether tolerance delays or promotes the eventual emergence of resistance is unclear. Here we used in vitro evolution experiments to explore this question. We found that in all cases, tolerance preceded resistance. A mathematical population-genetics model showed how tolerance boosts the chances for resistance mutations to spread in the population. Thus, tolerance mutations pave the way for the rapid subsequent evolution of resistance. Preventing the evolution of tolerance may offer a new strategy for delaying the emergence of resistance.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Drug Resistance, Multiple, Bacterial/genetics , Drug Tolerance , Ampicillin/pharmacology , Bacteria/genetics , Bacterial Proteins/genetics , DNA Mutational Analysis , Directed Molecular Evolution , Escherichia coli/drug effects , Escherichia coli/genetics , Evolution, Molecular , Mutation , Promoter Regions, Genetic , beta-Lactamases/genetics
5.
Methods Mol Biol ; 1333: 75-81, 2016.
Article in English | MEDLINE | ID: mdl-26468101

ABSTRACT

The present method quantifies the number of slow-growing bacteria leading to antibiotic persistence in a clonal population. First, it enables discriminating between slow growers that are generated by exposure to a stress signal (Type I persisters) and slow growers that are continuously generated during exponential growth (Type II persisters). Second, the method enables determining the amount of slow growers in a culture.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cell Culture Techniques/methods , Drug Resistance, Bacterial/genetics , Escherichia coli/drug effects , Drug Resistance, Bacterial/drug effects , Escherichia coli/growth & development , Humans
6.
J Vis Exp ; (89)2014 Jul 15.
Article in English | MEDLINE | ID: mdl-25077667

ABSTRACT

Growth dynamics are fundamental characteristics of microorganisms. Quantifying growth precisely is an important goal in microbiology. Growth dynamics are affected both by the doubling time of the microorganism and by any delay in growth upon transfer from one condition to another, the lag. The ScanLag method enables the characterization of these two independent properties at the level of colonies originating each from a single cell, generating a two-dimensional distribution of the lag time and of the growth time. In ScanLag, measurement of the time it takes for colonies on conventional nutrient agar plates to be detected is automated on an array of commercial scanners controlled by an in house application. Petri dishes are placed on the scanners, and the application acquires images periodically. Automated analysis of colony growth is then done by an application that returns the appearance time and growth rate of each colony. Other parameters, such as the shape, texture and color of the colony, can be extracted for multidimensional mapping of sub-populations of cells. Finally, the method enables the retrieval of rare variants with specific growth phenotypes for further characterization. The technique could be applied in bacteriology for the identification of long lag that can cause persistence to antibiotics, as well as a general low cost technique for phenotypic screens.


Subject(s)
Bacteriological Techniques/methods , High-Throughput Screening Assays/methods , Escherichia coli/growth & development
7.
Nat Methods ; 7(9): 737-9, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20676109

ABSTRACT

We developed an automated system, ScanLag, that measures in parallel the delay in growth (lag time) and growth rate of thousands of cells. Using ScanLag, we detected small subpopulations of bacteria with dramatically increased lag time upon starvation. By screening a library of Escherichia coli deletion mutants, we achieved two-dimensional mapping of growth characteristics, which showed that ScanLag enables multidimensional screens for quantitative characterization and identification of rare phenotypic variants.


Subject(s)
Escherichia coli/growth & development , Image Processing, Computer-Assisted/methods , Automation , Escherichia coli/genetics , Gene Library , Genetic Variation , Mutation , Phenotype
8.
Proc Natl Acad Sci U S A ; 107(28): 12541-6, 2010 Jul 13.
Article in English | MEDLINE | ID: mdl-20616060

ABSTRACT

In the face of antibiotics, bacterial populations avoid extinction by harboring a subpopulation of dormant cells that are largely drug insensitive. This phenomenon, termed "persistence," is a major obstacle for the treatment of a number of infectious diseases. The mechanism that generates both actively growing as well as dormant cells within a genetically identical population is unknown. We present a detailed study of the toxin-antitoxin module implicated in antibiotic persistence of Escherichia coli. We find that bacterial cells become dormant if the toxin level is higher than a threshold, and that the amount by which the threshold is exceeded determines the duration of dormancy. Fluctuations in toxin levels above and below the threshold result in coexistence of dormant and growing cells. We conclude that toxin-antitoxin modules in general represent a mixed network motif that can serve to produce a subpopulation of dormant cells and to supply a mechanism for regulating the frequency and duration of growth arrest. Toxin-antitoxin modules thus provide a natural molecular design for implementing a bet-hedging strategy.


Subject(s)
Escherichia coli/genetics , Escherichia coli/physiology , Anti-Bacterial Agents/pharmacology , Antitoxins/genetics , Antitoxins/pharmacology , Bacteria/genetics , Bacteria/metabolism , Escherichia coli/growth & development , Glycogen Storage Disease Type IIb/genetics , Myopathy, Central Core/genetics , Optic Atrophy, Autosomal Dominant/genetics , Urea Cycle Disorders, Inborn
SELECTION OF CITATIONS
SEARCH DETAIL
...